PRQR250117P7500
- 0.00
- 0.000.00%
ProQR Therapeutics Newsroom
Is There An Opportunity With ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 37% Undervaluation?
ProQR Therapeutics N.V. (NASDAQ:PRQR) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely
Chardan Capital Maintains ProQR Therapeutics(PRQR.US) With Buy Rating, Maintains Target Price $4
ProQR Therapeutics Expands Collaboration With RSRT With $8.1 Mln Funding For AX-2402
ProQR Therapeutics Is Maintained at Buy by Chardan Capital
H.C. Wainwright Maintains ProQR Therapeutics(PRQR.US) With Buy Rating, Maintains Target Price $10
ProQR Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
JMP Securities Maintains ProQR Therapeutics(PRQR.US) With Buy Rating, Maintains Target Price $8
ProQR Therapeutics Advances Axiomer RNA-Editing Platform With Strategic Partnerships
ProQR Receives $9.1M to Develop RNA Therapy for Rett Syndrome, Impacting 350,000 People
Express News | ProQR Therapeutics Announces $8.1 Million in New Funding From Rett Syndrome Research Trust to Expand Rna Editing Collaboration
ProQR Therapeutics Announces $8.1 Million in New Funding From Rett Syndrome Research Trust to Expand RNA Editing Collaboration
ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist
JMP Securities Maintains ProQR Therapeutics(PRQR.US) With Buy Rating, Raises Target Price to $8
ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024
ProQR Therapeutics Price Target Raised to $8 From $5 at JMP Securities
H.C. Wainwright Maintains ProQR Therapeutics(PRQR.US) With Buy Rating, Raises Target Price to $10
Express News | ProQR Therapeutics N.V. : H.c. Wainwright Raises Target Price to $10 From $5
Chardan Capital Maintains ProQR Therapeutics(PRQR.US) With Buy Rating, Announces Target Price $4
ProQR Therapeutics Shows Revenue Growth Amid Financial Challenges